The profile of drug treatment in subjects aged over 50 years with hypertension in an urban russian population

Objective To analyze a profile of hypotensive drug therapy in patients with arterial hypertension (АH) aged 55–84 in a sample of urban population at a current period of time (2015–2017).

Materials and Methods AH is a leader among risk factors of cardiovascular diseases (CVD) due to its high prevalence and serious prognosis. Despite the availability of effective hypotensive drugs and guidelines on AH treatment, 50% of patients do not achieve blood pressure (BP) goals. Knowledge about drug correction of AH in the Russian population is limited to clinical studies. Taking into account changing approaches in management of patients with AH, the population-based evaluation of hypotensive treatment if relevant. A random population sample of males and females aged 55-84 (n=3.898) was evaluated in Novosibirsk in 2015-2017 (international project, Health, Alcohol and Psychosocial Factors in Eastern Europe (HAPIEE)). AH was diagnosed in presence of systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg and/or treatment with hypotensive drugs within the recent two weeks. Regular intake of medication for 12 months was evaluated with coding according to the Anatomic Therapeutic Chemical Classification System (АТХ / АТС).

Results In the population sample aged 55–84, AH prevalence was 80.9 %, and 21.1 % of persons with AH did not receive drug therapy. Hypotensive medicines included (total/as a part of combination therapy) angiotensin-converting enzyme (ACE) inhibitors (42.3 % / 25.3 %), angiotensin II receptor blockers (ARBs) (30.3 % / 18.9 %), diuretics (22.6 % / 20.4 %), calcium channel blockers (20.2 % / 16.1 %), and beta-blockers (34.7 % / 27.6 %). 45.7 % of people with AH received a combination therapy. Effective BP control was achieved in 23.4 % of AH patients and in 29.6 % of patients receiving a hypotensive therapy. In the group of ineffective BP control, the proportion of females was lower, AH duration was longer, and blood glucose was higher than in the group of effective control.

Conclusion In the sample of urban population aged 55–84 in 2015–2017, each fourth participant with AH and each third participant using hypotensive drugs achieved effective BP control. The therapy profile in AH patients included recommended drug classes. However, combination therapy was used insufficiently (50% of AH patients). By frequency of use, ACE inhibitors were on the first place, beta-blockers were on the second place, ARBs were on the third place, diuretics were on the fourth place, and calcium channel blockers were on the fifth place, which differed from the guidelines (the difference from the recommended priority ranking is that the drugs taking the first places in the guidelines were in fact on the 3rd and 4th places in their actual frequency of use). 20% of persons with AH did not receive hypotensive therapy, which significantly contributed to the insufficient BP control in the population.

1. World Health Organization. A global brief of hypertension. Silent killer, global public health crisis. World health day. 2013. [Document number: WHO/DCO/WHD/2013.2. Av. at: http://ish-world.com/downloads/pdf/global_brief_hypertension.pdf]

2. Zhou B, Bentham J, Di Cesare M, Bixby H, Danaei G, Cowan MJ et al. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. The Lancet. 2017;389(10064):37–55. DOI: 10.1016/S0140-6736(16)31919-5

3. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 2017;317(2):165–82. DOI: 10.1001/jama.2016.19043

4. World Health Organization. European health for all database (HFA-DB) [electronic resource]. 2005. [Av. at: https://apps.who.int/iris/handle/10665/108565]

5. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of Hypertension. 2018;36(10):1953–2041. DOI: 10.1097/HJH.0000000000001940

6. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. The Lancet. 2005;365(9455):217–23. DOI: 10.1016/S0140-6736(05)17741-1

7. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet (London, England). 2002;360(9349):1903–13. PMID: 12493255

8. Vishram JKK, Borglykke A, Andreasen AH, Jeppesen J, Ibsen H, Jørgensen T et al. Impact of Age on the Importance of Systolic and Diastolic Blood Pressures for Stroke Risk: The MOnica, Risk, Genetics, Archiving, and Monograph (MORGAM) Project. Hypertension. 2012;60(5):1117–23. DOI: 10.1161/HYPERTENSIONAHA.112.201400

9. Brown D, Giles W, Greenlund K. Blood Pressure Parameters and Risk of Fatal Stroke, NHANES II Mortality Study. American Journal of Hypertension. 2007;20(3):338–41. DOI: 10.1016/j.amjhyper.2006.08.004

10. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology. 2018;71(19):e127–248. DOI: 10.1016/j.jacc.2017.11.006

11. Chazova I.E., Zhernakova Yu.V. Clinical guidelines Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6–31. [Russian: Чазова И.Е., Жернакова Ю.В. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019;16(1):6-31]. DOI: 10.26442/2075082X.2019.1.190179

12. Kotseva K, De Backer G, De Bacquer D, Rydén L, Hoes A, Grobbee D et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. European Journal of Preventive Cardiology. 2019;26(8):824–35. DOI: 10.1177/2047487318825350

13. Zhang Y, Moran AE. Trends in the Prevalence, Awareness, Treatment, and Control of Hypertension Among Young Adults in the United States, 1999 to 2014. Hypertension. 2017;70(4):736–42. DOI: 10.1161/HYPERTENSIONAHA.117.09801

14. Joffres M, Falaschetti E, Gillespie C, Robitaille C, Loustalot F, Poulter N et al. Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. BMJ Open. 2013;3(8):e003423. DOI: 10.1136/bmjopen-2013-003423

15. Muromtceva G.A., Kontsevaya A.V., Konstantinov V.V., Artamonova G.V., Gatagonova T. M., Duplyakov D.V. et al. The prevalence of non-infectious disease risk factors in the Russian population in 2012-2013. Results of the ESSE-RF study. Cardiovascular Therapy and Prevention. 2014;13(6):4–11. [Russian: Муромцева Г.А., Концевая А.В., Константинов В.В., Артамонова Г.В., Гатагонова Т.М., Дупляков Д.В. и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012–2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярная терапия и профилактика. 2014;13(6):4-11]. DOI: 10.15829/1728-8800-2014-6-4-11

16. Boytsov S.A., Balanova Yu.A., Shal’nova S.A., Deev A.D., Artamonova G.V., Gatagonova T.M. et al. Arterial hypertension among persons aged 25-64: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4–14. [Russian: Бойцов С.А., Баланова Ю.А., Шальнова С.А., Деев А.Д., Артамонова Г.В., Гагатонова Т.М. и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль по материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014;13(4):4-14]. DOI: 10.15829/1728-8800-2014-4-4-14

17. Peasey A, Bobak M, Kubinova R, Malyutina S, Pajak A, Tamosiunas A et al. Determinants of cardiovascular disease and other non-communicable diseases in Central and Eastern Europe: Rationale and design of the HAPIEE study. BMC Public Health. 2006;6(1):255. DOI: 10.1186/1471-2458-6-255

18. Rehm J. Measuring Quantity, Frequency, and Volume of Drinking. Alcoholism: Clinical and Experimental Research. 1998;22(s2):4s–14s. DOI: 10.1111/j.1530-0277.1998.tb04368.x

19. Cardiovascular Survey Methods. Rose GA, editor -Genève: WHO;1984. - 188 p. ISBN 978-92-4-240056-4

20. Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). European Heart Journal. 2013;34(39):3035–87. DOI: 10.1093/eurheartj/eht108

21. WHO Collaborating Centre for Drug Statistics Methodology. ATC Index with DDDs. [Internet] Available at: https://www.whocc.no/atc_ddd_index_and_guidelines/atc_ddd_index/

22. Hopstock LA, Eggen AE, Løchen M-L, Mathiesen EB, Nilsen A, Njølstad I et al. Blood pressure target achievement and antihypertensive medication use in women and men after first-ever myocardial infarction: the Tromsø Study 1994–2016. Open Heart. 2018;5(1):e000746. DOI: 10.1136/openhrt-2017-000746

23. Zhou B, Danaei G, Stevens GA, Bixby H, Taddei C, Carrillo-Larco RM et al. Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. The Lancet. 2019;394(10199):639–51. DOI: 10.1016/S0140-6736(19)31145-6

24. Martsevich S.Yu., Lukina Yu.V., Zagrebelnyy A.V., Loukianov M.M., Vorobyev A.N., Pravkina E.A. et al. Combined Antihypertensive Therapy in Real Clinical Practice. Focus on Fixed Combinations of Antihypertensive Drugs (According to the Data of Outpatient Registries RECVASA and PROFILE). Rational Pharmacotherapy in Cardiology. 2017;13(3):323–9. [Russian: Марцевич С.Ю., Лукина Ю.В., Загребельный А.В., Лукьянов М.М., Воробьев А.Н., Правкина Е.А. и др. Комбинированная антигипертензивная терапия в реальной клинической практике. Фокус на фиксированные комбинации антигипертензивных препаратов (по данным амбулаторных регистров РЕКВАЗА и ПРОФИЛЬ). Рациональная фармакотерапия в кардио­логии. 2017;13(3):323-9]. DOI: 10.20996/1819-6446-2017-13-3-323-329

25. Shalnova S.A., Konradi A.O., Balanova Yu.A., Deev A.D., Imaeva A.E., Muromtseva G.A. et al. What factors do influence arterial hypertension control in Russia. Cardiovascular Therapy and Prevention. 2018;17(4):53–60. [Russian: Шальнова С.А., Конради А.О., Баланова Ю.А., Деев А.Д., Имаева А.Э., Муромцева Г.А. и др. Какие факторы влияют на контроль артериальной гипертонии в России. Кардиоваскулярная терапия и профилактика. 2018;17(4):53-60]. DOI: 10.15829/1728-8800-2018-4-53-60

26. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and Apparent Treatment Resistant Hypertension in the United States, 1988 to 2008. Circulation. 2011;124(9):1046–58. DOI: 10.1161/CIRCULATIONAHA.111.030189

27. Kim T-H, Yang P-S, Yu HT, Jang E, Shin H, Kim HY et al. Effect of hypertension duration and blood pressure level on ischaemic stroke risk in atrial fibrillation: nationwide data covering the entire Korean population. European Heart Journal. 2019;40(10):809–19. DOI: 10.1093/eurheartj/ehy877

28. Chung S-C, Pujades-Rodriguez M, Duyx B, Denaxas SC, Pasea L, Hingorani A et al. Time spent at blood pressure target and the risk of death and cardiovascular diseases. PLOS ONE. 2018;13(9):e0202359. DOI: 10.1371/journal.pone.0202359

29. Sakboonyarat B, Mungthin M. Prevalence and associated factors of uncontrolled hypertension among Thai patients with hypertension: A nationwide cross-sectional survey. Revue d’Épidémiologie et de Santé Publique. 2018;66(5):S310–1. DOI: 10.1016/j.respe.2018.05.194

30. Shalnova S.A., Deev A.D., Balanova Yu.A., Kapustina A.V., Imaeva A.E., Muromtseva G.A. et al. Twenty years trends of obesity and arterial hypertension and their association in Russia. Cardiovascular Therapy and Prevention. 2017;16(4):4–10. [Russian: Шальнова С.А., Деев А.Д., Баланова Ю.А., Капустина А.В., Имаева А.Э., Муромцева Г.А. и др. Двадцатилетние тренды ожирения и артериальной гипертонии и их ассоциации в России. Кардиоваскулярная терапия и профилактика. 2017;16(4):4-10]. DOI: 10.15829/1728-8800-2017-4-4-10